Liraglutide evidence, regulatory status, intended use, known risks, and limitations.
Regulatory status
FDA-approved drug for product-specific indications
Quick verdict
An evidence-backed prescription option for its specific FDA-approved indication. Individual decisions require a licensed clinician.
At a glance
Primary use: Chronic weight management or type 2 diabetes, depending on product. Evidence strength: Strong — FDA-reviewed clinical program. Prescription treatment and clinician supervision are required.
What it is
Liraglutide is a GLP-1 receptor agonist used in FDA-approved prescription products with different labeled indications.
What it’s used for
Chronic weight management or type 2 diabetes, depending on product
How it works
Mechanism and pharmacology are described in the current FDA prescribing information; this review does not provide dosing instructions.
Clinical evidence
Strong — FDA-reviewed clinical program. Public claims on this page are limited to the cited regulatory and clinical evidence.
FDA / Regulatory status
FDA-approved drug for product-specific indications
Administration
Once-daily subcutaneous injection. Prescription required. Coverage, prior authorization, availability, and patient cost vary. Novo Nordisk publicly lists Saxenda at $1,349.02 per package and documents eligibility-limited savings support. FDA has approved generic liraglutide products, but pharmacy availability and coverage should be verified.
Potential benefits
FDA-reviewed evidence supports product-specific benefits for labeled indications.
Known risks & side effects
FDA labeling includes a boxed warning about thyroid C-cell tumors observed in rodents and other product-specific warnings.
Contraindications / Important warnings
FDA labeling includes a boxed warning about thyroid C-cell tumors observed in rodents and other product-specific warnings.
Who it may be appropriate for
Potentially appropriate only for patients who meet product-specific labeled criteria after clinician assessment.
Evidence gaps
Evidence for one product should not be transferred to every formulation or off-label use.
Alternatives
Review established options for the relevant goal and discuss clinically appropriate alternatives with a licensed professional.
Score breakdown
Editorial score 8.7/10 — Clinical Evidence 9; Regulatory Status 10; Effectiveness Evidence 8.5; Safety / Known Risks 7.5; Access & Convenience 7.5; Cost Transparency 8.5. Weighted using the published methodology.
Final verdict
A legitimate prescription therapy for specific approved uses, with important product-specific risks and limitations.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.